Lymphoma and leukemia cell therapy by humanized antibodies

Research unit

INNOSUISSE

Project number

46049.1 IP-LS

Project title

Lymphoma and leukemia cell therapy by humanized antibodies

Texts for this project

	German	French	Italian	English
Short description		-	-
Abstract		-	-	-

Category	Text
Short description (German)	Lymphoma and leukemia cell therapy by humanized antibodies
Short description (English)	Lymphoma and leukemia cell therapy by humanized antibodies
Abstract (German)	Abologix developed humanized monoclonal antibodies (mAbs) directed against the adhesion molecule C (JAM-C), a novel cancer target expressed on multiple B-cell lymphomas and leukemia cells. Classical treatment often fails due to resistance, but JAM-C still can be targeted and used for rescue.